MiMedx Group (MDXG) Stock Price, Quote, News & History | Benzinga

MiMedx Group Inc (MDXG) Stock Price, Quote, News & History

MDXGNASDAQ

Trade with Public

Trade with Public

$3.43

0.082.39%

At close: Apr 24, 5:00 PM EST

$3.38

-0.0491-1.43%

After Hours: Apr 24, 6:00 PM EST

Earnings: Q1 2026 Earnings in 3 days from now on Wed Apr 29th, after the market close

Conference Call: Conference call scheduled in 3 days at 4:30 PM

Click to view the webcast

OverviewNews Earnings Options Guidance Analyst Ratings Insider Trades Short Interest Stock Report

Key Statistics

Open

$3.34

Close

$3.43

Volume / Avg.

1.69M / 1.17M

Day Range

$3.29 - $3.50

52 Wk Range

3.19 - 7.99

Market Cap

$500.72M

P/E Ratio

10.48

Dividend Yield

-

Exchange

NASDAQ

RSI

30

Short Interest

6.29%

Days to Cover

6.23

Recent MiMedx Group Inc News

Analyst Bullish On MiMedx's Rapid Growth In $4B Woundcare Market With Innovative Skin Substitutes

Cantor Fitzgerald has initiated coverage on MIMEDX, highlighting its strong market presence in wound care and surgical recovery. Targeting a $3.9 billion market, MIMEDX products demonstrate a 97% wound closure rate for diabetic foot ulcers, cost-effectiveness, and significant growth potential.

Vandana Singh

MiMedx Targets Profitability with Strategic Realignment, Suspends Knee Osteoarthritis Program Activities

MiMedx Group Inc (NASDAQ: MDXG) announced a strategic realignment to focus its resources on its Wound & Surgical business, driving profitability and

Vandana Singh

The Daily Biotech Pulse: Leap, Phio, Silverback Among Early Movers On Oncology Conference Presentations, Aerie Slumps On Mixed Data, Axsome Commences Phase 3 Sleep Disorder Study

Here's a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech Stocks Hitting 52-week Highs Sept. 15)

Shanthi Rexaline

Financials

Quarterly

Annual

Name

Revenue Change
Gross Change
EBITDA Change
EBIT Change
Earnings Change

Cash Flows

Operating Cash Flow (TTM)

74.00M

Investing Cash Flow (TTM)

-6.89M

Financing Cash Flow (TTM)

-5.41M

Free Cash Flow (TTM)

72.97M

Capital Expenditure (TTM)

-1.03M

Net Change in Cash (TTM)

61.71M

Analyst Trends and Forecast

1

Dec 25

1

Jan

1

Feb

1

Apr

Buy

Hold

Sell

Strong Sell

Analyst Rating and Forecast

4.4

Buy

Strong Buy

Buy

Hold

Sell

Strong Sell

Valuation Metrics

Enterprise Value

$361.43M

PE Ratio (TTM)

10.48

PE Ratio (FWD)

-

PEG Ratio (TTM)

-

PS Ratio (TTM)

1.20

PB Ratio (TTM)

1.94

Earnings Yield % (TTM)

9.54%

Earnings Yield % (FWD)

-

EV / EBITDA (TTM)

4.45

Price / EBITDA (TTM)

6.38

Price / Free Cash Flow (TTM)

6.88

Book Value / Share

$1.73

Company Debt

Total Debt

$17.97M

LT Debt

$16.47M

LT Debt Issuance (TTM)

$0

LT Debt Repayment (TTM)

-$1.00M

Total Cash

$166.12M

Debt to Equity

0.07

Issuance of Debt (TTM)

-$1.00M

Repayment of Debt (TTM)

-$1.00M

Key Statistics

Open

$3.34

Close

$3.43

Volume / Avg.

1.69M / 1.17M

Day Range

$3.29 - $3.50

52 Wk Range

3.19 - 7.99

Market Cap

$500.72M

P/E Ratio

10.48

Dividend Yield

-

Exchange

NASDAQ

RSI

30

Short Interest

6.29%

Days to Cover

6.23

About

Sector

Health Care

Industry

Biotechnology

MiMedx Group Inc develops and markets regenerative biomaterial products and bioimplants made from the human amniotic membrane, birth tissues, and human skin & bone. Its products are targeted towards the wound-care, burn, surgical, sports medicine, an...

Show More

Edge Rankings

Stock Score Locked: Want to See it?

Benzinga Rankings give you vital metrics on any stock – anytime.

Reveal Full Score

Compare

EPS worse than industry

Earnings Per Share

EPS is the portion of a company's profit allocated to each outstanding share of common stock. It is a key metric for investors to assess a company's profitability.

Earnings Per Share

EPS is the portion of a company's profit allocated to each outstanding share of common stock. It is a key metric for investors to assess a company's profitability.

EPS worse than industry

FAQ

Q

How do I buy MiMedx Group (MDXG) stock?

A

You can purchase shares of MiMedx Group (NASDAQ:MDXG) through any online brokerage.

View our list of the best stock brokerages

Q

Who are MiMedx Group (MDXG) competitors?

A

Other companies in MiMedx Group’s space includes: Zura Bio Ltd (NASDAQ:ZURA), Tectonic Therapeutic Inc (NASDAQ:TECX), 4D Molecular Therapeutics Inc (NASDAQ:FDMT), Valneva SE (NASDAQ:VALN) and Upstream Bio Inc (NASDAQ:UPB).

Q

What is the forecast, or price target, for MiMedx Group (MDXG) stock?

A

MiMedx Group has a consensus price target of $9.29.

Q

What is the current price for MiMedx Group (MDXG)?

A

The stock price for MiMedx Group (NASDAQ: MDXG) is $3.3809 last updated April 24, 2026 at 6:00 PM EDT.

Q

Does MiMedx Group (MDXG) pay a dividend?

A

There are no upcoming dividends for MiMedx Group.

Q

When is MiMedx Group (NASDAQ:MDXG) reporting earnings?

A

MiMedx Group does not have any upcoming earnings scheduled.

Q

Is MiMedx Group (MDXG) going to split?

A

There is no upcoming split for MiMedx Group.

Q

What sector and industry does MiMedx Group (MDXG) operate in?

A

MiMedx Group is in the Health Care sector and Biotechnology industry. They are listed on the NASDAQ.

People Also Watch

Tectonic Therapeutic Inc

4D Molecular Therapeutics Inc

Upstream Bio Inc

Larimar Therapeutics Inc

Armata Pharmaceuticals Inc

ADC Therapeutics SA